Biophytis to Participate in Four Key Events in Q4 2025
Biophytis announces its participation in four major international events that reflect the complementarity of its development strategy:
- CF&B Midcap Events
- Paris, September 30 – October 1, 2025
- Geneva, December 10, 2025
- BIO-Europe (Vienna, November 3–5, 2025)
- SCWD Annual Conference (Rome, December 11–13, 2025)
In Paris and Geneva, the Company will take part in the Midcap Events organized by CF&B, a leading platform for listed companies to engage with a wide range of institutional investors specializing in small and midcaps. Biophytis will present its recent progress, particularly in sarcopenia and obesity, and engage with the financial community on its development outlook.
In Vienna, Biophytis will participate in BIO-Europe 2025, the largest biotechnology partnering event in Europe, bringing together key stakeholders across the pharmaceutical and biopharmaceutical value chain. The Company will seize the opportunity to meet potential new industrial partners, explore possible collaborations, and lay the groundwork for strategic alliances to support its clinical development programs.
In Rome, Biophytis will attend the annual conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD), a major international scientific event focused on muscle-wasting conditions related to aging and chronic diseases. This participation comes in the context of the upcoming launch of the Phase 3 SARA trial in sarcopenia, the most advanced clinical program in this indication worldwide. The Company will present its research and aims to strengthen its positioning within the medical and academic communities.
A Pivotal Fourth Quarter for Biophytis
With active participation in four major events, Biophytis reaffirms its ambition to be a central player in the development of transformative therapies impacting longevity. These events represent key opportunities to initiate new partnerships, enhance the visibility of its clinical programs, and secure the resources needed to support their advancement.